RCT | Efficacy of 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide for treatment of fluoroquinolone-sensitive MDR-TB.
9 Nov, 2022 | 12:11h | UTC9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea – The Lancet (link to abstract – $ for full-text)